Global Migraine Drugs Market: Overview
About 12–14% of people around the world suffer from a Migraine; it is a type of a headache. According to regional and international rules, migraine is classified by the nature of the attack and its frequency into a chronic migraine and episodic migraine. Prophylactic and abortive are 2 treatments available for the relief of this headache type. Prophylactic treatment is offered to patients suffering from a chronic migraine in order to avoid migraine attacks utilizing medications like topiramate, botulinum toxin, and others. Abortive treatment is offered to terminate severe migraine attack and includes medication like ergot alkaloids, triptans, and others.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
Global Migraine Drugs Market: Growth Factors
The increasing awareness regarding a migraine and various options available for its treatment are the major factors boosting the growth of the global migraine drugs market. A number of organizations including the American Headache and Migraine Association are taking efforts to spread awareness about a migraine and hence coming up with programs and providing support to patients so as to spread awareness regarding the disease and further disorders related to a headache. Due to the increasing number of migraine incidences and rising number of unmet needs in the global migraine drugs market, a number of companies are planning to invest in the migraine drugs R&D. This, in turn, is anticipated to propel the global migraine drugs market growth in the near future.
Global Migraine Drugs Market: Segmentation
The global migraine drugs market is segmented on the basis of treatment type, route of administration, and distribution channel. On the basis of treatment type, the global migraine drugs market is segmented as prophylactic and abortive. The prophylactic treatment segment is further sub-segmented as topiramate, botulinum toxin, and others. The abortive treatment segment is further sub-segmented as ergot alkaloids, triptans, and others. On the basis of route of administration, the global market is classified as injectable, oral, and others. The others segment is further sub-segmented as transdermal patches and nasal sprays. On the basis of the distribution channel, the global migraine drugs market is diversified as hospital pharmacies, retail pharmacies, and others.
Global Migraine Drugs Market: Regional Analysis
The Asia Pacific is anticipated to dominate the global migraine drugs market and is further expected to continue this trend in the near future. This high growth is mainly owing to the increasing number of people having from a migraine and rising public awareness of the disease in this region. In addition, China and India are the major developing countries contributing to the global migraine drugs market growth in the Asia Pacific region; this is mainly due to the high occurrence of a migraine in these countries. Rising focus on niche products and their launches along with high penetration of novel drug manufacturers will further have a positive impact on the growth of the global migraine drugs market in the near future.
Global Migraine Drugs Market: Competitive Players
Some of the major players in the global migraine drugs market include Endo, Allergan, Impax Laboratories, Glaxo Smith Kline, Astellas, Amgen, Bayer, AstraZeneca, Dr. Reddy's Laboratories, Zogenix, CoLucid, Eli Lilly, Eisai, IntelGenx, Ethypharm, and Klaria. Other key players dominating the global market are Johnson & Johnson, Luitpold Pharmaceuticals, Kowa Pharmaceuticals America, Merck, Meda, Pfizer, OptiNose, Raptor, Pozen, SUDA, RedHill, TG Therapeutics, Teva, Winston Pharmaceuticals, and NValeant.
Global Migraine Drugs Market: Regional Segment Analysis
What Reports Provides
Request the coronavirus impact analysis across industries and markets